Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They set a “buy” rating and a $18.00 price target on the stock. Cantor Fitzgerald upped their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Trading Up 3.4 %

Shares of NASDAQ:VNDA opened at $5.19 on Friday. The company’s 50 day moving average is $4.79 and its two-hundred day moving average is $5.24. The company has a market cap of $302.53 million, a PE ratio of -18.54 and a beta of 0.77. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. The business had revenue of $47.65 million for the quarter, compared to analysts’ expectations of $47.50 million. Vanda Pharmaceuticals had a negative return on equity of 3.01% and a negative net margin of 8.59%. As a group, equities research analysts expect that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 7.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock valued at $3,663,000 after buying an additional 55,567 shares during the period. Empowered Funds LLC lifted its holdings in Vanda Pharmaceuticals by 5.3% in the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company’s stock valued at $1,071,000 after acquiring an additional 11,524 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at about $143,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth approximately $40,000. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.